Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus Published: Jul 24, 2023 In an exciting development, Orthogon Therapeutics LLC, a leading player in the field of antiviral therapeutics, has achieved a significant breakthrough. The company's flagship molecule has successfully completed acute toxicity studies, marking a majo..
DiaCarta Inc., a leading molecular diagnostic test developer for cancer and infectious diseases, has announced a strategic partnership with Hopkins MedTech Compliance (HMC) and Hopkins MedTech Lab Services (HML) to address the regulatory compliance and laboratory developed test (LDT) validation needs in the United States. This collaboration aims to provide support to companies that have develope..
Enveric Biosciences (NASDAQ: ENVB) has announced positive findings from preclinical studies that support the metabolic profile of its leading candidate, EB-373. The absorption, distribution, metabolism, and excretion (ADME) as well as toxicology assays have demonstrated rapid conversion of EB-373 to the active metabolite psilocin. These results are consistent with previous animal pharmacokinetic..
Myriad Genetics, a leader in genetic testing and precision medicine, has recently announced an exciting update to their MyRisk® with RiskScore® Breast Cancer Risk Assessment. This comprehensive risk model now includes breast density as a key factor, along with personal/family history and genetic markers. By incorporating this additional information, patients and healthcare providers can gain a m..
PaxMedica, a clinical stage biopharmaceutical company, has announced positive top line results from the PAX-101 Phase 3 African Sleeping Sickness study. The study successfully achieved its primary endpoint and demonstrated statistically significant and clinically meaningful results. These findings are an important step towards filing an NDA for the use of PAX-101 in the treatment of African Slee..
Syndax Pharmaceuticals Inc. (Nasdaq: SNDX) and Incyte Corporation (Nasdaq: INCY) have announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in chronic graft-versus-host disease (GVHD). The trial successfully met its primary endpoint, demonstrating an overall response rate (ORR) of 74% when administered at a dose of 0.3 mg/kg every two weeks. Furthermore, the data reve..